When was HIBio founded?

HIBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is HIBio located?

HIBio is headquartered in Foshan, China.

Who is the current CEO of HIBio?

Travis Murdoch of HIBio. They have also founded 1 company.

Is HIBio a funded company?

HIBio is a funded company, having raised a total of $215M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Nov 01, 2022.

How much is HIBio worth?

The last known valuation of HIBio was $***** as of May 23, 2024.

When was the latest funding round of HIBio?

HIBio's latest funding was a $***** Series B round on Jan 04, 2024, with participation from 5 investors. Its primary sector is Immunology. In China, the Immunology sector has seen $324M in funding in 2026 to date.

Where does HIBio rank among its competitors?

HIBio ranks 141st amongst 431 active competitors, of which 139 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of HIBio?

HIBio's top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

HIBio - 2026 Company Profile, Team, Funding & Competitors

Q: Is HIBio an acquired company?

HIBio got acquired by Biogen on May 22, 2024.

HIBio is an acquired company based in Foshan (China), founded in 2021 by Travis Murdoch. It operates as a Developer of precision medicines for autoimmune and inflammatory diseases. HIBio has raised $215M in funding from investors like Arch Venture Partners, Jeito and Monograph, with last known valuation of $*****. The company has 431 active competitors, including 139 funded and 117 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Key Metrics

Founded Year

2021

Location

Foshan, China

Stage

Acquired

Total Funding

$215M in 2 rounds

Latest Funding Round

Series B, Jan 04, 2024, $*****

Last Known Valuation

$***** as on May 23, 2024

Investors

Arch Venture Partners & 5 more

Ranked

141^st among 431 active competitors

Similar Companies

BeiGene & 501 more

Exit Details

Acquired by Biogen (May 22, 2024)

View HIBio's full profile

HIBio got acquired by Biogen on May 22, 2024 at an acquisition amount of $*****.

Click here to take a look at HIBio's acquisition in detail

HIBio has raised a total funding of $215M over 2 rounds. Its first funding round was on Nov 01, 2022. Its latest funding round was a Series B round on Jan 04, 2024 for $*****. 5 investors participated in its latest round. HIBio has 6 institutional investors.

Here is the list of recent funding rounds of HIBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 04, 2024	5109670	Series B	3249307	6899264	1171182	6199333
Nov 01, 2022	1305637	Series B	1883420	2682143	Arch Venture Partners & 2 more	6382644

Access funding benchmarks and valuations. Sign up today!

View details of HIBio's funding rounds and investors

The founders of HIBio is Travis Murdoch. Travis Murdoch is the CEO of HIBio.

Here are the details of HIBio's key team members:

Travis Murdoch: Founder & CEO of HIBio.
Contact Info: 1 email address

View details of HIBio's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HIBio include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of HIBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
141st	HIBio 2021, Foshan (China), Acquired	Developer of precision medicines for autoimmune and inflammatory diseases	$215M	Alpha Wave Global, Arch Venture Partners & 4 others	42/100